Skip to main content
OpenTrials
Completed

NCT Number: NCT06097182

Post-biotic Intervention for Acute Stress Management

The study aims to evaluate the sub-chronic effects of colonic delivery of a post-biotic on stress response, mood state, sleep, and cognition in healthy young subjects with elevated self-reported stress levels. It is hypothesized that oral intake of the post-biotic, when released in the colonic intestinal site, leads to a blunted subjective and objective stress response after a stress induction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Human Development Research Centre, SICS, A*STAR

Singapore, 117597

About this study

Scientific findings over the past years suggest that certain bacteria in our gastrointestinal system have an influence on our mood, although, the mechanisms are not yet well understood. One of the possibilities is that bacteria produce compounds that interact with neurons in the gut. These neurons could subsequently send signals to the brain.

This study is a proof of principle study examining the effects of a post-biotic in the distal intestinal tract (terminal ileum, colon) on stress response, mood state, sleep, and cognition. The study is expected to provide key insights in the potential of treatment strategies aimed at stimulating the colonic enteric nervous system to exert mood enhancement. It is hypothesized that interactions with the local Enteric Nervous System leading to stress reduction, mood enhancement and sleep promotion effects. The study will employ an in-person clinic visit, in addition to traditional self-reported, behavioural, and physiological outcome measures; exploratory digital health outcomes will also be included to identify novel objective mood/stress measures.

This study seeks to recruit a total of 75 healthy males (25 in each arm), between the ages of 21-30 years old (inclusive) from local community outreach in Singapore over a period 12 months. This study is a hybrid study (partially decentralized).

The total duration of participation from each participant will be 9 days (excluding, the screening and enrolment days).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 21 to 30 years
  • Men
  • Perceived Stress Scale (PSS-10) score >13
  • Own and uses a smartphone that is capable to run the study applications with access to the internet
  • Adequate fluency in the English language to understand the inform consent process, study instructions and study assessments
  • Sufficient vision and hearing to complete study procedures
  • Willing to commit to the study procedures
  • Willing and able to participate and to give written informed consent All inclusion criteria will be assessed based on self-reported information during the screening visit.

Exclusion criteria

  • Past (< 6 months prior to the study) or current major neurological, psychiatric, gastrointestinal, metabolic disease or cardiovascular disease
  • Past (<1 months prior to the study) or current use of psychoactive medication, cardiovascular medication, or corticosteroids.
  • Known medical history of hypotension or currently on antihypertensive medication
  • Alcohol intake >1 units day
  • Present or past history of alcohol or drug addiction and/or recreational drug use
  • BMI <18.5 or >25 kg/m2
  • Maltodextrin allergy
  • Members of the research team or their immediate family members. An immediate family member is defined as spouse, parent, child, or sibling, whether biological or legally adopted All exclusion criteria will be assessed based on self-reported information during the screening call.

Treatment and study plan

Post-biotic (Colonic-Delivery capsule)

Dietary Supplement

250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)

Post-biotic (Regular Administration capsule)

Dietary Supplement

250mg post-biotic once daily in a regular uncoated vegan gelatine capsule

Placebo

Other

250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule

Primary outcomes

  1. Salivary Cortisol

    Time frame: Day 7 (5/day)

    cortisol levels, as a marker of hypothalamic-pituitary-adrenal (HPA) axis activation

Secondary outcomes

  1. State Trait Anxiety Inventory (STAI-6)

    Time frame: Day 7 (2/day)

    The STAI-6 is a validated short-form version (6 items) of the 40-item STAI questionnaire, measuring current anxiety symptoms on a 4-point Likert scale. Total score is calculated (range 6-24).

  2. The Brunel Mood Scale (BRUMS)

    Time frame: Day 7 (2/day)

    The BRUMS is a 24-item questionnaire of simple mood descriptors such as angry, nervous, unhappy, and energetic. The BRUMS has six subscales, with each of the subscales containing four mood descriptors. The subscales are anger, confusion, depression, fatigue, tension, and vigour. Responses are recorded using a 5-point Likert scale (0-4).

  3. Heart Rate

    Time frame: Days 1-7

    Measured as beats per minute. Continuous monitoring via a smart-watch.

  4. Sleep Activity

    Time frame: Days 1-7

    During sleep, the activity will be monitored via a smart-watch throughout the sleep session.

Other outcomes

  1. Ecological Momentary Assessments (EMA)

    Time frame: Day 1-6 (4/day), Day 7 (2/day), Day 8 (1/day)

    Subjects are asked to indicate their current state on a visual analogue scale ranging from 'not at all' to 'very much' using a slider.

  2. Salivary α-amylase

    Time frame: Day 7 (5/day)

    α-amylase levels, as a marker of autonomic nervous system activation

  3. Gastrointestinal Symptoms

    Time frame: Days 1-7 (1/day)

    Participants will be asked to rate the average severity of the following five symptoms over the preceding 24 hours on a 5-point scale from 0 (absent) to 4 (very severe): bloating/distension, passage of gas, rumbling, feeling of fullness and abdominal discomfort/pain. A daily total score is calculated by summing all items recorded each day. A lower score is concomitant with lower severity of symptoms.

  4. Respiratory Rate

    Time frame: Days 1-7

    Measured as how many breaths per minute. Continuous monitoring via a smart-watch.

  5. Electrodermal Activity (EDA)

    Time frame: Days 1-7

    4 user-initiated 2 min sessions per day. Measured via a smart-watch and the total score per session is provided by the watch.

  6. Speech Analysis for digital stress biomarkers

    Time frame: Day 7 (2/day)

    Subjects are requested to verbally reproduce an orally presented standard short story from Newcomer Story Set. A high-resolution video with audio will be recorded and exploratory analyses of speech characteristics will be performed.

  7. Eye Movement Analysis for digital stress biomarkers

    Time frame: Day 7 (2/day)

    Subjects are requested to verbally reproduce an orally presented standard short story from Newcomer Story Set. A high-resolution video with audio will be recorded and exploratory analyses of eye movements will be performed.

  8. Facial Expression Analysis for digital stress biomarkers

    Time frame: Day 7 (2/day)

    Subjects are requested to verbally reproduce an orally presented standard short story from the Newcomer Story Set. A high-resolution video with audio will be recorded and exploratory analyses of facial characteristics will be performed.

  9. Handwriting Analysis for digital stress biomarkers

    Time frame: Day 7 (2/day)

    Subjects are requested to write down words of a specific category with a specified starting letter. As an exploratory outcome, a digital picture of the written text will be analyzed for handwriting characteristics such as trace, calibre, slant, and distance.

  10. Cognitive performance

    Time frame: Days 1-8

    Cognitive performance will be assessed with a short (5 min) test battery consisting of tests of processing speed, spatial memory, and reaction time delivered through a mobile application that was developed to assess individuals' cognition in natural, non-laboratory, settings.

Sponsors and collaborators

Lead sponsor

Institute for Human Development and Potential (IHDP), Singapore

Other

Registry information

Acronym: PIAS

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 24, 2023
Registry last updated
Aug 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.